About this trial
This study is making a registry to help doctors understand how to choose the best treatments for pancreatic cancer using a method called irreversible electroporation (IRE). The goal is to gather information about treatment outcomes and complications. This will help doctors provide better care to patients who need surgery for pancreatic cancer.
The trial's ID number is NCT02674100. This is an observational study, meaning it looks at real-world outcomes without changing treatment. About 500 participants are expected to join this study.
Who can join
Adults aged 18 and older with pancreatic cancer may join. They must be eligible for soft tissue ablation as decided by their doctor. Some people cannot join, such as those with certain heart devices or those not able to have general anesthesia. The trial team will check who is eligible.
Condition
Pancreatic Cancer
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be part of a registry. This means their information will be collected over time to understand the safety and effects of IRE treatment. The registry will track any adverse events for up to 5 years after treatment.
Where
This trial is running at 11 locations in the United States. All of them are currently recruiting.
Atlantic Health
Millburn, New Jersey
Augusta University
Augusta, Georgia
Gibbs Cancer Research, Spartanburg Regional Healthcare System
Spartanburg, South Carolina
Johns Hopkins Hospital
Baltimore, Maryland
Methodist Digestive Institute
Dallas, Texas
Northwell Health Cancer Institute
Lake Success, New York
University of Alabama Birmingham
Birmingham, Alabama
University of California San Diego
San Diego, California
The first 8 of 11 sites are listed here. The registry record has the full list.